




RealRate

MEDICINAL PRODUCTS 2021

Chemours Co
Rank 32 of 52





MEDICINAL PRODUCTS 2021

Chemours Co
Rank 32 of 52



The relative strengths and weaknesses of Chemours Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemours Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Chemours Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 69% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	2,633,000
Assets, Non-Current	808,000
General and Administrative Expense	4,429,000
Goodwill	153,000
Liabilities, Current	1,478,000
Liabilities, Non-Current	4,789,000
Other Assets	14,000
Other Compr. Net Income	39,000
Other Expenses	250,000
Other Liabilities	0
Other Net Income	22,000
Other Revenues	4,969,000
Property, Plant and Equipment, Net	3,474,000
Research and Development	93,000

Output Variable	Value in 1000 USD
Liabilities	6,267,000
Assets	7,082,000
Expenses	4,772,000
Revenues	4,969,000
Stockholders Equity	815,000
Net Income	219,000
Comprehensive Net Income	238,500
Economic Capital Ratio	14%